DE4419315A1
(de)
*
|
1994-06-01 |
1995-12-07 |
Merckle Gmbh |
Heteropyrrolizinverbindungen und deren Anwendung in der Pharmazie
|
DE4419247A1
(de)
*
|
1994-06-01 |
1995-12-07 |
Merckle Gmbh |
Sulfonylierte Pyrrolizincarbonsäureamide und deren Anwendung in der Pharmazie
|
DE4419246A1
(de)
*
|
1994-06-01 |
1995-12-07 |
Merckle Gmbh |
Heteroarylsubstituierte Pyrrolizinverbindungen und deren Anwendung in der Pharmazie
|
WO1999012930A1
(en)
*
|
1997-09-05 |
1999-03-18 |
Glaxo Group Limited |
2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors
|
RS49982B
(sr)
*
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
US6040450A
(en)
*
|
1997-09-25 |
2000-03-21 |
Merck & Co., Inc. |
Process for making diaryl pyridines useful as cox-2-inhibitors
|
FR2770131A1
(fr)
*
|
1997-10-27 |
1999-04-30 |
Union Pharma Scient Appl |
Nouvelle association pharmaceutique a activite analgesique
|
FR2771005B1
(fr)
*
|
1997-11-18 |
2002-06-07 |
Union Pharma Scient Appl |
Nouvelle association pharmaceutique a activite analgesique
|
US7041694B1
(en)
|
1997-12-17 |
2006-05-09 |
Cornell Research Foundation, Inc. |
Cyclooxygenase-2 inhibition
|
ATE323491T1
(de)
|
1997-12-22 |
2006-05-15 |
Euro Celtique Sa |
Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
BR9915011A
(pt)
*
|
1998-11-03 |
2001-08-07 |
Glaxo Group Ltd |
Compostos, método para a preparação dos mesmos, composição farmacêutica, métodos de tratamento de um indivìduo humano ou animal sofrendo de uma condição que é mediada pela inibição seletiva de cox-2 e sofrendo de um distúrbio inflamatório, e, uso de um composto
|
US6833373B1
(en)
|
1998-12-23 |
2004-12-21 |
G.D. Searle & Co. |
Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
US6649645B1
(en)
|
1998-12-23 |
2003-11-18 |
Pharmacia Corporation |
Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
JP2002538157A
(ja)
*
|
1999-02-27 |
2002-11-12 |
グラクソ グループ リミテッド |
ピラゾロピリジン
|
ATE283048T1
(de)
*
|
1999-12-08 |
2004-12-15 |
Pharmacia Corp |
Cyclooxygenase-2 hemmer enthaltende zusammensetzungen mit schnellem wirkungseintritt
|
GB9930358D0
(en)
|
1999-12-22 |
2000-02-09 |
Glaxo Group Ltd |
Process for the preparation of chemical compounds
|
DE10004157A1
(de)
|
2000-02-01 |
2001-08-02 |
Merckle Gmbh Chem Pharm Fabrik |
4-Pyridyl-und 2,4-Pyrimidinyl-substituierte Pyrrolderivate und ihre Anwendung in der Pharmazie
|
EP1935421A1
(en)
|
2000-02-08 |
2008-06-25 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
DK2283842T3
(en)
|
2000-02-08 |
2015-05-26 |
Euro Celtique Sa |
Oral opioid agonist formulations secured against forgery
|
CA2414674A1
(en)
*
|
2000-07-13 |
2002-01-24 |
Pharmacia Corporation |
Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
|
PE20020506A1
(es)
*
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
AU2001290243A1
(en)
*
|
2000-09-20 |
2002-04-02 |
Nikken Chemicals Co., Ltd. |
Novel thiazole bicyclic compounds
|
AU2002239348A1
(en)
*
|
2000-12-15 |
2002-06-24 |
Glaxo Group Limited |
Pyrazolopyridine derivatives
|
JP2004518651A
(ja)
*
|
2000-12-15 |
2004-06-24 |
グラクソ グループ リミテッド |
治療用化合物
|
US7115565B2
(en)
*
|
2001-01-18 |
2006-10-03 |
Pharmacia & Upjohn Company |
Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
|
DE60201074T2
(de)
*
|
2001-03-08 |
2005-09-15 |
Smithkline Beecham Corp. |
Pyrazolopyridinderivate
|
JP4237497B2
(ja)
*
|
2001-03-30 |
2009-03-11 |
スミスクライン ビーチャム コーポレーション |
ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
|
JP2004525150A
(ja)
*
|
2001-03-30 |
2004-08-19 |
スミスクライン ビーチャム コーポレーション |
治療用化合物としてのピラゾロピリジン類の使用
|
US7695736B2
(en)
|
2001-04-03 |
2010-04-13 |
Pfizer Inc. |
Reconstitutable parenteral composition
|
ITMI20010733A1
(it)
|
2001-04-05 |
2002-10-05 |
Recordati Chem Pharm |
Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
|
EP1377575B1
(en)
*
|
2001-04-10 |
2006-07-05 |
SmithKline Beecham Corporation |
Antiviral pyrazolopyridine compounds
|
EP1385847B1
(en)
*
|
2001-04-27 |
2005-06-01 |
SmithKline Beecham Corporation |
Pyrazolo[1,5-a]pyridine derivatives
|
US6756498B2
(en)
|
2001-04-27 |
2004-06-29 |
Smithkline Beecham Corporation |
Process for the preparation of chemical compounds
|
UA81224C2
(uk)
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
ATE493130T1
(de)
|
2001-05-11 |
2011-01-15 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
ES2271273T3
(es)
*
|
2001-06-21 |
2007-04-16 |
Smithkline Beecham Corporation |
Derivados imidazo-1,2-aipiridina para la profilaxis y tratamiento de las infecciones del virus del herpres.
|
MXPA04000584A
(es)
|
2001-07-18 |
2004-04-20 |
Euro Celtique Sa |
COMBINACIONES FARMACeUTICAS DE OXICODONA Y NALOXONA.
|
CA2450073C
(en)
|
2001-07-25 |
2017-08-29 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for modulating blood-brain barrier transport
|
PT1414451E
(pt)
|
2001-08-06 |
2009-07-31 |
Euro Celtique Sa |
Formulações agonistas de opióides com antagonista libertável e sequestrado
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
UA80682C2
(en)
*
|
2001-08-06 |
2007-10-25 |
Pharmacia Corp |
Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
|
AR038957A1
(es)
|
2001-08-15 |
2005-02-02 |
Pharmacia Corp |
Terapia de combinacion para el tratamiento del cancer
|
ES2286272T3
(es)
*
|
2001-09-07 |
2007-12-01 |
Smithkline Beecham Corporation |
Pirizolo-piridinas para el tratamiento de infecciones por herpes.
|
US7244740B2
(en)
*
|
2001-10-05 |
2007-07-17 |
Smithkline Beecham Corporation |
Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
|
DE60222465T2
(de)
*
|
2001-12-11 |
2008-06-05 |
Smithkline Beecham Corp. |
Pyrazolopyridin-derivate als antiherpesmittel
|
ES2627298T3
(es)
|
2002-04-05 |
2017-07-27 |
Mundipharma Pharmaceuticals S.L. |
Preparación farmacéutica que contiene oxicodona y naloxona
|
AU2003230965B2
(en)
|
2002-04-17 |
2008-02-21 |
The Cleveland Clinic Foundation |
Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
|
JP4514606B2
(ja)
|
2002-05-09 |
2010-07-28 |
ザ ブライハム アンド ウイメンズ ホスピタル, インコーポレイテッド |
心血管疾患マーカーおよび治療標的としてのil1rl−1
|
AU2003229016A1
(en)
*
|
2002-05-10 |
2003-11-11 |
The Trustees Of Columbia University In The City Of New York |
Genetically engineered cell lines and systems for propagatingvaricella zoster virus and methods of use thereof
|
US20040021778A1
(en)
*
|
2002-08-05 |
2004-02-05 |
Oldani Jerome L. |
Security system with remote access and control
|
PT1551372T
(pt)
|
2002-09-20 |
2018-07-23 |
Alpharma Pharmaceuticals Llc |
Subunidade de sequestração e composições e métodos relacionados
|
EP1546148A1
(en)
*
|
2002-10-03 |
2005-06-29 |
SmithKline Beecham Corporation |
Therapeutic compounds based on pyrazolopyridine derivatives
|
WO2005000194A2
(en)
|
2002-10-08 |
2005-01-06 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
|
AU2003285864C1
(en)
*
|
2002-10-08 |
2010-07-01 |
Rinat Neuroscience Corp. |
Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
|
US9498530B2
(en)
|
2002-12-24 |
2016-11-22 |
Rinat Neuroscience Corp. |
Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
|
KR101410692B1
(ko)
|
2002-12-24 |
2014-06-24 |
리나트 뉴로사이언스 코프. |
항-ngf 항체 및 그것을 이용하는 방법
|
US7569364B2
(en)
*
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
EP2191846A1
(en)
|
2003-02-19 |
2010-06-02 |
Rinat Neuroscience Corp. |
Method for treating pain by administering a nerve growth factor antagonist and an NSAID and composition containing the same
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
AU2004266705A1
(en)
*
|
2003-08-20 |
2005-03-03 |
Nitromed, Inc. |
Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
|
AU2004270162B2
(en)
*
|
2003-08-28 |
2010-05-13 |
Nicox S.A. |
Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
|
SI2384753T1
(sl)
|
2003-08-29 |
2016-06-30 |
The Brigham And Women's Hospital, Inc. |
Hidantoinski derivati kot inhibitorji celične nekroze
|
EP2298303A1
(en)
|
2003-09-25 |
2011-03-23 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
KR100647583B1
(ko)
*
|
2003-10-07 |
2006-11-17 |
삼성에스디아이 주식회사 |
이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
|
WO2005044227A1
(en)
*
|
2003-11-05 |
2005-05-19 |
Glenmark Pharmaceuticals Limited |
Topical pharmaceutical compositions
|
US20050100594A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Nilendu Sen |
Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
|
EP2306192B1
(en)
|
2003-12-05 |
2015-10-14 |
The Cleveland Clinic Foundation |
Risk Markers For Cardiovascular Disease
|
CA2554716A1
(en)
*
|
2004-01-22 |
2005-08-04 |
Nitromed, Inc. |
Nitrosated and/or nitrosylated compounds, compositions and methods of use
|
PT2206728T
(pt)
*
|
2004-04-07 |
2018-04-17 |
Rinat Neuroscience Corp |
Métodos de tratamento da dor associada ao cancro ósseo através da administração de um anticorpo antagonista do fator de crescimento nervoso
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
CA2569958C
(en)
|
2004-06-12 |
2016-03-22 |
Jane C. Hirsh |
Abuse-deterrent drug formulations
|
WO2006041855A2
(en)
|
2004-10-04 |
2006-04-20 |
Nitromed, Inc. |
Compositions and methods using apocynin compounds and nitric oxide donors
|
DK1809759T3
(da)
|
2004-10-06 |
2014-01-06 |
Brigham & Womens Hospital |
Relevans af opnåede niveauer af markører for systemisk inflammation efter behandling
|
AU2005304770A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Nicox S.A. |
Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
|
WO2006055542A2
(en)
*
|
2004-11-15 |
2006-05-26 |
Nitromed, Inc. |
Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
|
US20080306041A1
(en)
*
|
2005-01-21 |
2008-12-11 |
Garvey David S |
Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
|
JP2008530226A
(ja)
*
|
2005-02-16 |
2008-08-07 |
ニトロメッド インコーポレーティッド |
抗微生物化合物の有機酸化窒素供与体塩、組成物、および使用法
|
AU2006218766A1
(en)
*
|
2005-02-28 |
2006-09-08 |
Nicox S.A. |
Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
AU2006223392A1
(en)
*
|
2005-03-09 |
2006-09-21 |
Nicox S.A. |
Organic nitric oxide enhancing salts of angiotensin II antagonists, compositions and methods of use
|
PT1889198E
(pt)
|
2005-04-28 |
2015-03-06 |
Proteus Digital Health Inc |
Sistema fármaco-informático
|
US20090048219A1
(en)
*
|
2005-05-23 |
2009-02-19 |
Nitromed Inc. |
Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
|
US20090018091A1
(en)
*
|
2005-08-02 |
2009-01-15 |
Nitromed, Inc. |
Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
|
AU2006299383A1
(en)
*
|
2005-10-04 |
2007-04-12 |
Nitromed, Inc. |
Methods for treating respiratory disorders
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
US7838023B2
(en)
*
|
2005-11-16 |
2010-11-23 |
Nitromed, Inc. |
Furoxan compounds, compositions and methods of use
|
WO2007075541A2
(en)
*
|
2005-12-20 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
|
WO2007075542A2
(en)
*
|
2005-12-22 |
2007-07-05 |
Nitromed, Inc. |
Nitric oxide enhancing pyruvate compounds, compositions and methods of use
|
ES2641879T3
(es)
|
2006-03-15 |
2017-11-14 |
The Brigham And Women's Hospital, Inc. |
Uso de gelsolina para diagnosticar y tratar enfermedades inflamatorias
|
WO2007126609A1
(en)
|
2006-03-29 |
2007-11-08 |
Nitromed, Inc. |
Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
|
US20080057590A1
(en)
|
2006-06-07 |
2008-03-06 |
Mickey Urdea |
Markers associated with arteriovascular events and methods of use thereof
|
PT2526932T
(pt)
|
2006-06-19 |
2017-08-10 |
Alpharma Pharmaceuticals Llc |
Composição farmacêutica
|
US8795627B2
(en)
|
2007-03-21 |
2014-08-05 |
Raptor Pharmaceuticals Inc. |
Treatment of liver disorders by administration of RAP conjugates
|
ES2434215T3
(es)
|
2007-04-18 |
2013-12-16 |
Tethys Bioscience, Inc. |
Biomarcadores relacionados con la diabetes y métodos de uso de los mismos
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
GB2460915B
(en)
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
|
US20100160351A1
(en)
*
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
WO2010071865A1
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
|
WO2010095940A2
(en)
|
2009-02-20 |
2010-08-26 |
To-Bbb Holding B.V. |
Glutathione-based drug delivery system
|
KR20110133602A
(ko)
|
2009-03-10 |
2011-12-13 |
유로-셀티큐 에스.에이. |
옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
|
NZ596876A
(en)
|
2009-05-06 |
2014-01-31 |
Lab Skin Care Inc |
Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
|
FR2945289A1
(fr)
*
|
2009-05-11 |
2010-11-12 |
Sanofi Aventis |
Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
|
WO2011032175A1
(en)
|
2009-09-14 |
2011-03-17 |
Nuon Therapeutics, Inc. |
Combination formulations of tranilast and allopurinol and methods related thereto
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
TW201201764A
(en)
|
2010-02-01 |
2012-01-16 |
Hospital For Sick Children |
Remote ischemic conditioning for treatment and prevention of restenosis
|
KR20190000368A
(ko)
|
2010-03-31 |
2019-01-02 |
더 호스피탈 포 식 칠드런 |
심근 경색 후 결과를 개선시키기 위한 원격 허혈 처치의 사용
|
DK3333188T3
(da)
|
2010-08-19 |
2022-03-07 |
Zoetis Belgium S A |
Anti-NGF-antistoffer og deres anvendelse
|
US20120077778A1
(en)
|
2010-09-29 |
2012-03-29 |
Andrea Bourdelais |
Ladder-Frame Polyether Conjugates
|
SG10201510564PA
(en)
|
2010-12-22 |
2016-01-28 |
Purdue Pharma Lp |
Encased tamper resistant controlled release dosage forms
|
ES2581323T3
(es)
|
2010-12-23 |
2016-09-05 |
Purdue Pharma Lp |
Formas de dosificación oral sólida resistentes a alteraciones
|
PL2710039T3
(pl)
|
2011-05-20 |
2019-07-31 |
Alderbio Holdings Llc |
Kompozycje przeciwko CGRP i ich zastosowanie
|
NZ701702A
(en)
|
2012-05-11 |
2017-07-28 |
Reset Therapeutics Inc |
Carbazole-containing sulfonamides as cryptochrome modulators
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
MX2015010041A
(es)
|
2013-02-05 |
2015-10-30 |
Purdue Pharma Lp |
Formulacion farmaceuticas resistentes a la alteracion.
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
WO2014145022A1
(en)
|
2013-03-15 |
2014-09-18 |
President And Fellows Of Harvard College |
Hybrid necroptosis inhibitors
|
JP2016525138A
(ja)
|
2013-07-23 |
2016-08-22 |
ユーロ−セルティーク エス.エイ. |
疼痛および腸内ディスバイオシスをもたらす疾患および/または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
|
GB201321731D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
EP3292213A1
(en)
|
2015-05-04 |
2018-03-14 |
Academisch Medisch Centrum |
Biomarkers for the detection of aspirin insensitivity
|
US10913783B2
(en)
|
2016-04-15 |
2021-02-09 |
H. Lundbeck A/S |
Humanized anti-PACAP antibodies and uses thereof
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
CN111819197A
(zh)
|
2018-03-12 |
2020-10-23 |
硕腾服务有限责任公司 |
抗ngf抗体及其方法
|
TWI811428B
(zh)
|
2018-08-21 |
2023-08-11 |
日商杏林製藥股份有限公司 |
雙環雜芳香環衍生物
|
JP2022501359A
(ja)
|
2018-09-19 |
2022-01-06 |
モデルナティーエックス, インコーポレイテッド |
Peg脂質及びそれらの使用
|
AU2019345067A1
(en)
|
2018-09-19 |
2021-04-08 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
US20240165148A1
(en)
|
2021-03-15 |
2024-05-23 |
Saul Yedgar |
Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
|
WO2023026245A1
(en)
|
2021-08-27 |
2023-03-02 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|